X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs AUROBINDO PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD AUROBINDO PHARMA ALEMBIC LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 51.4 19.4 264.7% View Chart
P/BV x 2.2 3.6 60.4% View Chart
Dividend Yield % 0.5 0.3 134.7%  

Financials

 ALEMBIC LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
AUROBINDO PHARMA
Mar-18
ALEMBIC LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs72809 8.9%   
Low Rs34504 6.7%   
Sales per share (Unadj.) Rs4.7281.1 1.7%  
Earnings per share (Unadj.) Rs6.141.4 14.8%  
Cash flow per share (Unadj.) Rs6.250.9 12.3%  
Dividends per share (Unadj.) Rs0.202.50 8.0%  
Dividend yield (eoy) %0.40.4 99.2%  
Book value per share (Unadj.) Rs40.7199.4 20.4%  
Shares outstanding (eoy) m267.03585.88 45.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.3 482.3%   
Avg P/E ratio x8.715.9 54.6%  
P/CF ratio (eoy) x8.512.9 65.7%  
Price / Book Value ratio x1.33.3 39.5%  
Dividend payout %3.36.0 54.2%   
Avg Mkt Cap Rs m14,139384,630 3.7%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m20721,308 1.0%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m1,255164,666 0.8%  
Other income Rs m3701,020 36.3%   
Total revenues Rs m1,625165,686 1.0%   
Gross profit Rs m11137,718 0.3%  
Depreciation Rs m385,580 0.7%   
Interest Rs m2777 0.2%   
Profit before tax Rs m44232,380 1.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m248,183 0.3%   
Profit after tax Rs m1,63024,229 6.7%  
Gross profit margin %8.922.9 38.6%  
Effective tax rate %5.425.3 21.5%   
Net profit margin %129.814.7 882.5%  
BALANCE SHEET DATA
Current assets Rs m1,867121,878 1.5%   
Current liabilities Rs m59186,806 0.7%   
Net working cap to sales %101.621.3 477.2%  
Current ratio x3.21.4 224.9%  
Inventory Days Days94130 72.6%  
Debtors Days Days7468 107.6%  
Net fixed assets Rs m1,79181,037 2.2%   
Share capital Rs m534586 91.2%   
"Free" reserves Rs m10,324116,218 8.9%   
Net worth Rs m10,858116,804 9.3%   
Long term debt Rs m414,512 0.9%   
Total assets Rs m11,591211,052 5.5%  
Interest coverage x260.942.7 611.5%   
Debt to equity ratio x00 9.8%  
Sales to assets ratio x0.10.8 13.9%   
Return on assets %14.111.8 118.8%  
Return on equity %15.020.7 72.4%  
Return on capital %15.227.4 55.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1980,727 0.0%   
Fx outflow Rs m26434,700 0.8%   
Net fx Rs m-24446,027 -0.5%   
CASH FLOW
From Operations Rs m23619,548 1.2%  
From Investments Rs m-224-19,570 1.1%  
From Financial Activity Rs m-278,642 -0.3%  
Net Cashflow Rs m-158,922 -0.2%  

Share Holding

Indian Promoters % 64.0 54.1 118.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.5%  
FIIs % 9.7 27.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.2 255.9%  
Shareholders   54,701 69,601 78.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  GLENMARK PHARMA  ORCHID PHARMA LTD  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Capital Infusion in PSBs, November WPI Inflation, and Top Cues in Focus Today(Pre-Open)

Indian share markets closed marginally higher on Friday. Gains were largely seen in the telecom sector and oil & gas sector, while healthcare stocks witnessed selling pressure.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Dec 14, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - STRIDES PHARMA SCIENCE COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS